DSP105

//DSP105
DSP105 2018-04-29T10:58:24+00:00

DSP105
(PD1-41BBL)

Discovery
KAHR-105 PD1 41BBL

Targeted immune activation leading to T-cell mediated tumor destruction

  • PD-L1 is highly expressed on tumors and in the tumor microenvironment, allowing tumors to evade the immune system
  • 41BB:41BBL interaction provides an immune stimulatory signal
  • DSP105 targets PD-L1 expressing tumor cells by blocking the corresponding immune checkpoint inhibitory signals while simultaneously activating the immune cells via the 41BBL pathway

DSP105 PD1-41BBL:  Mechanism of Action

PD1-41BBL DSP target PD-L1 expressing tumors, simultaneously delivering an immune stimulatory signal and blocking immune inhibitory signals

PD1-41BBL-DSP-target-PD-L1
MOA & in-vivo efficacy

MOA & in-vivo efficacy

  • DSP105 targets PD-L1 expressing tumors, simultaneously delivering an immune stimulatory signal and blocking immune inhibitory signals
  • Efficiently binds its targets PDL1 and 41BB in-vitro and on cells
  • Effectively activates 41BB signaling
  • Activates T cells in the presence of PD-L1 to secrete IFN-γ
CMC development

CMC development

  • CMC development of the human protein initiated
Toxicology: mouse & monkey studies

Clinical development

  • Potential as a therapeutic agent and/or as an ex-vivo treatment to support adoptive T-cell therapy is being evaluated